Plain-English translation of NCT06389292 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called lisaftoclax combined with azacitidine to treat acute myeloid leukemia (a serious blood cancer) in older adults who are not able to receive standard chemotherapy. Half of the participants will receive the medication plus azacitidine, while the other half will receive a placebo (a dummy pill) plus azacitidine. Researchers want to see if adding this treatment helps patients live longer and feel better.
Acute myeloid leukemia is a life-threatening blood cancer, but many older patients cannot tolerate the standard chemotherapy treatments because they are too strong. This trial exists to find a gentler but effective treatment option for these patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication plus azacitidine or a placebo plus azacitidine. Both are taken as pills by mouth. You will visit the study clinic regularly for blood tests, physical exams, and to receive your treatment. The study will monitor your health, cancer response, and any side effects throughout your participation.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Russia